Edited by Peter Hillerberg1 min readStories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Bullish options sentiment is loudest in semiconductors and biotech this week. A quiet but pointed defensive flow runs in the opposite direction.
NVIDIA sits at a 14-day RSI of 53 and has put on 23% year-to-date. Chip stocks staged a comeback on Friday after two days of pressure, and the ORTEX options score for the sector has turned positive over the past week. Analysts still see 43% upside, adding fuel to call-side interest.
Moderna is the biggest options story in the index calendar. ORTEX's Index Rebalance Radar puts an 81% probability on Moderna rejoining MSCI North America at the November review, with the ranking cut-off falling on 19 October. Forced buying of $3.3B is pencilled in if the addition is confirmed on 11 November. The stock has already risen 663% year-to-date. Options positioning ahead of that announcement date looks directional.
GameStop carries a 7.6-day days-to-cover and an ORTEX short score of 56. Analysts flag it as a consumer stock at risk of a sharp fall in October. The combination of heavy short interest and rising RSI of 72.5 is the setup that has historically attracted speculative call buying.
Dynatrace tops the ORTEX bullish options score table this week. The software name is up 47% year-to-date with RSI at 75. The positive options flow matches a stock running hard into near-term resistance.
On the defensive side, Vail Resorts and Quantum Computing show the weakest options sentiment of any liquid US names. Vail's 17.8-day DTC is the highest among names with meaningful options markets. Quantum Computing has fallen 27% in 2026 and carries a short score of 84.
Meanwhile, ORTEX alt data flagged an Xcel Energy reactor running 10 standard deviations below its own historical output on 11 October. Power supply shocks of that scale can move energy options markets fast. Traders watching utility vol should keep XEL on the radar.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
